[{"data":1,"prerenderedAt":64},["ShallowReactive",2],{"q-nurse-106-1-basic-medicine-039":3},{"subject":4,"subjectSlug":5,"subjectFullName":6,"question":7,"related":33,"lastmod":63},"基礎醫學","basic-medicine","基礎醫學(包括解剖學、生理學、病理學、藥理學、微生物學與免疫學)",{"id":8,"webId":9,"year":10,"session":11,"subject":4,"number":12,"stem":13,"options":14,"answer":19,"answerNote":20,"images":21,"explanation":22,"explanationDeep":23,"topics":24,"freq":11},"nurse-106-1-基礎醫學-039","nurse-106-1-basic-medicine-039",106,1,39,"目前肺癌的標靶治療，最主要是針對何種基因的突變？",{"A":15,"B":16,"C":17,"D":18},"p53","K-RAS","EGFR","Her2\u002FNeu","C",null,[],"本題考點為肺癌標靶治療的主要作用基因。依分子腫瘤學,非小細胞肺癌(尤其肺腺癌)常見表皮生長因子受體 EGFR 基因突變,以 gefitinib、erlotinib 等酪胺酸激酶抑制劑抑制其訊息傳遞,是目前肺癌標靶治療最主要標的,故正解為 C。p53 為抑癌基因,突變雖普遍卻無對應成熟標靶藥,A 錯。K-RAS 突變過去缺乏有效標靶且與 EGFR 抑制劑反應差,B 非主流。Her2\u002FNeu 主要用於乳癌與胃癌標靶,D 錯。","EGFR 屬受體酪胺酸激酶,突變使其持續活化下游 RAS-RAF-MEK 與 PI3K 生長訊號。TKI 藥名記憶:字尾 -tinib。亞洲、女性、不吸菸的肺腺癌 EGFR 突變率較高是常考流病特徵;另有 ALK、ROS1 融合基因對應不同標靶,可延伸複習。",[25,27,29,31],{"term":26,"count":11},"EGFR 突變",{"term":28,"count":11},"非小細胞肺癌",{"term":30,"count":11},"酪胺酸激酶抑制劑 TKI",{"term":32,"count":11},"標靶治療",[34,38,43,48,53,58],{"webId":35,"stem":36,"number":37,"year":10,"session":11},"nurse-106-1-basic-medicine-040","嬰兒最常見的先天性心臟病為下列那一種？",40,{"webId":39,"stem":40,"number":41,"year":10,"session":42},"nurse-106-2-basic-medicine-056","神經內科病人陳述時常嚴重單側頭痛，確診後為偏頭痛（migraine）。其治療處方為 sumatriptan，可使腦血管收縮，緩解頭痛。此藥物為下列何種自泌素之致效劑（agonist）？",56,2,{"webId":44,"stem":45,"number":46,"year":47,"session":11},"nurse-107-1-basic-medicine-070","下列何者是李斯特菌（Listeria monocytogenes）主要傳染途徑？",70,107,{"webId":49,"stem":50,"number":51,"year":52,"session":42},"nurse-108-2-basic-medicine-028","腎小球濾液與血漿的組成，主要差異為下列何者？",28,108,{"webId":54,"stem":55,"number":56,"year":57,"session":42},"nurse-109-2-basic-medicine-072","下列何者具有過濾血液中病原體以及清除衰老的血球細胞和血小板的功能？",72,109,{"webId":59,"stem":60,"number":61,"year":62,"session":11},"nurse-111-1-basic-medicine-026","下列有關人體缺血性休克後造成排尿量下降的主要原因，何者最不可能？",26,111,"2026-09-04",1788510691183]